State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

State Street Corp grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 15.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,317,936 shares of the company's stock after acquiring an additional 443,640 shares during the period. State Street Corp owned about 3.84% of IDEAYA Biosciences worth $105,112,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of IDYA. KBC Group NV grew its holdings in IDEAYA Biosciences by 29.1% during the 3rd quarter. KBC Group NV now owns 2,274 shares of the company's stock worth $72,000 after acquiring an additional 513 shares in the last quarter. Amalgamated Bank boosted its stake in shares of IDEAYA Biosciences by 22.9% during the third quarter. Amalgamated Bank now owns 2,840 shares of the company's stock valued at $90,000 after purchasing an additional 530 shares in the last quarter. US Bancorp DE increased its holdings in IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after buying an additional 689 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in IDEAYA Biosciences by 35.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company's stock worth $94,000 after buying an additional 796 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IDYA shares. Stephens assumed coverage on IDEAYA Biosciences in a report on Monday, November 18th. They issued an "overweight" rating and a $51.00 price target on the stock. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 5th. UBS Group began coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a "buy" rating and a $50.00 price target on the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Finally, Citigroup decreased their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Tuesday, August 27th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $53.67.

IDEAYA Biosciences Price Performance

IDYA traded up $0.86 on Monday, reaching $26.05. 730,688 shares of the stock were exchanged, compared to its average volume of 864,093. The company's 50-day moving average price is $28.66 and its 200 day moving average price is $34.30. The firm has a market capitalization of $2.25 billion, a PE ratio of -11.18 and a beta of 0.79. IDEAYA Biosciences, Inc. has a fifty-two week low of $24.72 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03. During the same period last year, the company posted ($0.46) EPS. As a group, equities analysts forecast that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.